|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naylor EC, Desani JK and Chung PK:
Targeted Therapy and Immunotherapy for Lung Cancer. Surg Oncol Clin
N Am. 25:601–609. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng M: Classification and pathology of
lung cancer. Surg Oncol Clin N Am. 25:447–468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao Y, Yang D, He J and Krasna MJ:
Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 25:439–445.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shan GP, Zhang P, Li P, Du FL and Yang YW:
Numb gene enhances radiation sensitivity of nonsmall cell lung
cancer stem sells. Cancer Biother Radiopharm. 31:180–188. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao C, Shen Y, Jin F, Miao Y and Qiu X:
Cancer stem cells in small cell lung cancer cell line H446: Higher
dependency on oxidative phosphorylation and mitochondrial
substrate-level phosphorylation than non-stem cancer cells. PLoS
One. 11:e01545762016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang KJ, Yang MH, Zheng JC, Li B and Nie
W: Arsenic trioxide inhibits cancer stem-like cells via
downregulation of Gli1 in lung cancer. Am J Transl Res.
8:1133–1143. 2016.
|
|
9
|
Fabregat I, Malfettone A and Soukupova J:
New insights into the crossroads between EMT and stemness in the
context of cancer. J Clin Med. 5:E372016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheridan C, Kishimoto H, Fuchs RK,
Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S and
Nakshatri H: CD44+/CD24− breast cancer cells
exhibit enhanced invasive properties: An early step necessary for
metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar
|
|
11
|
Jaggupilli A and Elkord E: Significance of
CD44 and CD24 as cancer stem cell markers: An enduring ambiguity.
Clin Dev Immunol. 2012:7080362012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu H, Wang YJ, Bian L, Fang ZH, Zhang QY
and Cheng JX: CD44+/CD24+ cervical cancer
cells resist radiotherapy and exhibit properties of cancer stem
cells. Eur Rev Med Pharmacol Sci. 20:1745–1754. 2016.PubMed/NCBI
|
|
13
|
Todoroki K, Ogasawara S, Akiba J, Nakayama
M, Naito Y, Seki N, Kusukawa J and Yano H:
CD44v3+/CD24− cells possess cancer stem
cell-like properties in human oral squamous cell carcinoma. Int J
Oncol. 48:99–109. 2016. View Article : Google Scholar
|
|
14
|
Salaria S, Means A, Revetta F, Idrees K,
Liu E and Shi C: Expression of CD24, a stem cell marker, in
pancreatic and small intestinal neuroendocrine tumors. Am J Clin
Pathol. 144:642–648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu H, Mu J, Xiao J, Wu X, Li M, Liu T and
Liu X: CD24 negative lung cancer cells, possessing partial cancer
stem cell properties, cannot be considered as cancer stem cells. Am
J Cancer Res. 6:51–60. 2015.
|
|
16
|
Roudi R, Madjd Z, Ebrahimi M, Samani FS
and Samadikuchaksaraei A: CD44 and CD24 cannot act as cancer stem
cell markers in human lung adenocarcinoma cell line A549. Cell Mol
Biol Lett. 19:23–36. 2014. View Article : Google Scholar
|
|
17
|
Karimi-Busheri F, Rasouli-Nia A,
Zadorozhny V and Fakhrai H: CD24+/CD38− as
new prognostic marker for non-small cell lung cancer. Multidiscip
Respir Med. 8:652013. View Article : Google Scholar
|
|
18
|
Majores M, Schindler A, Fuchs A, Stein J,
Heukamp L, Altevogt P and Kristiansen G: Membranous CD24 expression
as detected by the monoclonal antibody SWA11 is a prognostic marker
in non-small cell lung cancer patients. BMC Clin Pathol. 15:192015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia P, Gou WF, Zhao S and Zheng HC:
Crizotinib may be used in Lewis lung carcinoma: A novel use for
crizotinib. Oncol Rep. 30:139–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chu M, Guo J and Chen CY: Long-term
exposure to nicotine, via ras pathway, induces cyclin D1 to
stimulate G1 cell cycle transition. J Biol Chem. 280:6369–6379.
2005. View Article : Google Scholar
|
|
21
|
Alessandri G, Filippeschi S, Sinibaldi P,
Mornet F, Passera P, Spreafico F, Cappa PM and Gullino PM:
Influence of gangliosides on primary and metastatic neoplastic
growth in human and murine cells. Cancer Res. 47:4243–4247.
1987.PubMed/NCBI
|
|
22
|
Cavarra E, Bartalesi B, Lucattelli M,
Fineschi S, Lunghi B, Gambelli F, Ortiz LA, Martorana PA and
Lungarella G: Effects of cigarette smoke in mice with different
levels of alpha(1)-proteinase inhibitor and sensitivity to
oxidants. Am J Respir Crit Care Med. 164:886–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kristiansen G, Schlüns K, Yongwei Y,
Denkert C, Dietel M and Petersen I: CD24 is an independent
prognostic marker of survival in nonsmall cell lung cancer
patients. Br J Cancer. 88:231–236. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee HJ, Choe G, Jheon S, Sung SW, Lee CT
and Chung JH: CD24, a novel cancer biomarker, predicting
disease-free survival of non-small cell lung carcinomas: A
retrospective study of prognostic factor analysis from the
viewpoint of forthcoming (seventh) new TNM classification. J Thorac
Oncol. 5:649–657. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ayre DC, Pallegar NK, Fairbridge NA,
Canuti M, Lang AS and Christian SL: Analysis of the structure,
evolution, and expression of CD24, an important regulator of cell
fate. Gene. 590:324–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hermann PC, Sancho P, Cañamero M,
Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L,
Guerra C, et al: Nicotine promotes initiation and progression of
KRAS-induced pancreatic cancer via Gata6-dependent
dedifferentiation of acinar cells in mice. Gastroenterology.
147:1119–33.e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Veluchamy JP, Spanholtz J, Tordoir M,
Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD and van der
Vliet HJ: Combination of NK cells and cetuximab to enhance
anti-tumor responses in RAS mutant metastatic colorectal cancer.
PLoS One. 11:e01578302016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hrustanovic G and Bivona TG: RAS-MAPK
signaling influences the efficacy of ALK-targeting agents in lung
cancer. Mol Cell Oncol. 3:e10910612015. View Article : Google Scholar
|
|
29
|
Pallegar NK, Ayre DC and Christian SL:
Repression of CD24 surface protein expression by oncogenic Ras is
relieved by inhibition of Raf but not MEK or PI3K. Front Cell Dev
Biol. 3:472015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
